Back

Circulating transthyretin as an independent systemic vulnerability signal in transthyretin amyloidosis: insights from the French HEAR Registry

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Left ventricular hypertrophy: from hypertrophic cardiomyopathy to cardiac amyloidosis Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Assistant Professor Amira Zaroui

University Hospital Henri Mondor, Creteil (France)

5 More presentations in this session

Presentation thumbnail
Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort
Doctor M. Desai (Cleveland, US)
Abstract
Presentation thumbnail
Genetic status and response patterns to mavacamten: an echocardiographic signature of reverse remodeling from 3 portuguese centers
Doctor I. Miranda (Amadora, PT)
Abstract
Presentation thumbnail
Musculoskeletal events and risk of amyloidosis in the general population
Professor A. Tybjaerg-Hansen (Copenhagen, DK)
Abstract
Presentation thumbnail
Changes over time in AI-based echocardiographic metrics before and after therapy in ATTR cardiomyopathy
Ms A. Walser (Zurich, CH)
Abstract
Presentation thumbnail
LA cardiomyopathy in ATTR-CM: the incremental prognostic value of LA strain
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract

Access the full session

Session thumbnail
Left ventricular hypertrophy: from hypertrophic cardiomyopathy to cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center.
28 August 2020
thumbnail
Congress Session
What is the role of TTR in transthyretin amyloid cardiomyopathy?
2 September 2024
thumbnail
Congress Presentation
NT-proBNP and cardiopulmonary exercise testing parameters for risk stratification in ATTR-CM
5 April 2025
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources